---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-230760"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2024-10-02T23:59:59+00:00"
generated_at: "2026-05-30T22:47:17.491930+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vera expands atacicept program to broader IgAN and autoimmune kidney diseases with two new studies

## Summary
- ORIGIN Extend to start Q4 2024, providing extended atacicept access and long-term data for ORIGIN participants.
- PIONEER study in 2025 will evaluate atacicept in expanded IgAN populations (low eGFR, high/low proteinuria, recurrence post-transplant, adolescents) and podocytopathies (pMN, FSGS, MCD).
- Combined US peak prevalence of IgAN and autoimmune-driven pMN, FSGS, MCD estimated at ~230,000.
- 96-week Phase 2b ORIGIN data to be presented as Late Breaking Oral at ASN Kidney Week 2024.
- Multiple regulatory and clinical milestones expected over next 18 months.

## SEC filing metadata
- accession: 0001193125-24-230760
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2024-10-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312524230760/0001193125-24-230760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312524230760/d802938d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-230760
- JSON: https://secwatch.observer/filing/0001193125-24-230760.json
- Plain text: https://secwatch.observer/filing/0001193125-24-230760.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.